SignatureFD’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$188 Hold
10
– – ﹤0.01% 3477
2026
Q2
$219 Buy
+10
New +$208 ﹤0.01% 3411
2025
Q3
– Sell
-73
Closed -$684 – 3471
2025
Q2
$684 Sell
73
-1,321
-95% -$14.5K ﹤0.01% 3067
2025
Q1
$17.1K Sell
1,394
-684
-33% -$9.6K ﹤0.01% 2138
2024
Q4
$27.5K Sell
2,078
-1,745
-46% -$29.9K ﹤0.01% 1900
2024
Q3
$73.6K Buy
3,823
+89
+2% +$1.84K ﹤0.01% 1378
2024
Q2
$76.7K Sell
3,734
-190
-5% -$3.98K ﹤0.01% 1296
2024
Q1
$93.4K Buy
3,924
+176
+5% +$3.92K ﹤0.01% 1231
2023
Q4
$81K Buy
3,748
+3,622
+2,875% +$55.7K ﹤0.01% 1222
2023
Q3
$1.83K Sell
126
-23
-15% -$435 ﹤0.01% 2795
2023
Q2
$3.12K Sell
149
-57
-28% -$1.19K ﹤0.01% 2660
2023
Q1
$4.35K Buy
206
+136
+194% +$3.38K ﹤0.01% 2563
2022
Q4
$1.78K Hold
70
– – ﹤0.01% 2846
2022
Q3
$2K Hold
70
– – ﹤0.01% 2844
2022
Q2
$1K Buy
70
+18
+35% +$300 ﹤0.01% 3008
2022
Q1
$1K Buy
+52
New +$876 ﹤0.01% 3060
2021
Q4
– Sell
-42
Closed -$1K – 3261
2021
Q3
$1K Buy
+42
New +$700 ﹤0.01% 2921

Other funds holding SNDX

SignatureFD's SNDX Position: Q3 2026 in Review

SignatureFD held its Syndax Pharmaceuticals (SNDX) position steady in Q3 2026 at 10 shares worth $188. The position accounts for ﹤0.01% of the portfolio, ranked #3477.

SignatureFD first reported a position in SNDX in Q3 2021 and has held it in 17 quarters since. The position peaked at $93.4K in Q1 2024. 237 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • SignatureFD held 10 shares of Syndax Pharmaceuticals worth $188 as of Q3 2026.
  • SignatureFD left its Syndax Pharmaceuticals share count unchanged in Q3 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3477 holding.
  • SignatureFD first reported a position in Syndax Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
  • SignatureFD's Syndax Pharmaceuticals position peaked at $93.4K in Q1 2024.
  • 237 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.